Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda’s Velcade Reaches $1 Billion Blockbuster Status

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical's Velcade (bortezomib) for treating multiple myeloma officially reached blockbuster status in November, hitting the $1 billion mark in sales. The drug, co-marketed by its Millennium Pharmaceutical subsidiary and U.S.-based Johnson & Johnson, added sales in part by gaining an additional indication from U.S. FDA beyond it previous limit to patients who failed to respond to other drugs. The huge sales were realized despite the drug's $40,000 average price tag for a nine-month treatment. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067607

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel